Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Copenhagen Other stock markets			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

24-05-30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
22-06-28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Market Cap	10.46B 68.63B 9.18B 8.46B 7.91B 14.84B 987B 15.11B 102B 39.33B 486B 39.26B 38.4B 1,690B	P/E 2017	-154x	P/E 2018	-708x
Enterprise Value	10.49B 68.82B 9.21B 8.49B 7.93B 14.88B 989B 15.15B 102B 39.44B 488B 39.38B 38.51B 1,695B	EV / Sales 2017	49.4x	EV / Sales 2018	95.8x
Free-Float	10%	Yield 2017 *	-	Yield 2018	-

24-05-30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
22-06-28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI
21-04-25	Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	CI
20-02-17	Veloxis Pharmaceuticals A/S Announces Board Appointments	CI
20-02-07	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	CI
20-01-30	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
20-01-30	Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	CI
20-01-13	Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	CI
19-11-25	Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call
19-11-24	Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	CI
19-11-13	Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019
19-11-12	Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
19-10-30	Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	CI

21-06-02	Scandion Oncology A/S : appoints Johnny Stilou as new CFO	AQ
20-02-17	Veloxis Pharmaceuticals A/S : Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020	AQ
20-01-29	Veloxis Pharmaceuticals A/S : Nasdaq Copenhagen A/S has Accepted Veloxis Pharmaceuticals A/S' Request for Delisting of its Shares from Nasdaq Copenhagen A/S	AQ
20-01-27	Veloxis Pharmaceuticals A/S : Notice on Compulsory Acquisition to the Shareholders of Veloxis Pharmaceuticals A/S	AQ
20-01-27	Veloxis Pharmaceuticals A/S : - Major Shareholder Notifications	AQ

Veloxis Pharmaceuticals A/S Stock

Stocks

VELO

DK0060048148

Pharmaceuticals

Valuation: Veloxis Pharmaceuticals A/S

Latest news : Veloxis Pharmaceuticals A/S

Press Releases: Veloxis Pharmaceuticals A/S

News in other languages: Veloxis Pharmaceuticals A/S

Managers and Directors: Veloxis Pharmaceuticals A/S

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	2017-09-12
Stacy Wheeler COO	Chief Operating Officer	-	2016-02-29

Director	Title	Age	Since
Keigo Nakatsukasa CHM	Chairman	-	-
Yusuke Hiramatsu BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
MERCK & CO., INC.	+4.02%	+10.17%	+57.46%	+9.47%	298B
MERCK KGAA	+4.93%	+10.48%	+33.21%	-3.89%	69.19B
HALOZYME THERAPEUTICS, INC.	+2.09%	+5.96%	+38.83%	+112.76%	8.44B
KYOWA KIRIN CO., LTD.	+0.84%	+1.77%	+4.36%	-5.45%	8.27B
SK BIOPHARMACEUTICALS CO., LTD.	+2.31%	-0.11%	-4.11%	+4.85%	4.4B
BETTA PHARMACEUTICALS CO., LTD.	+4.94%	+12.50%	+7.58%	+29.39%	3.64B
YUHAN CORPORATION	-1.38%	-8.82%	-30.10%	+29.30%	3.5B
SUPERNUS PHARMACEUTICALS, INC.	-0.86%	+0.83%	+43.25%	+37.14%	2.62B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+2.36%	+10.87%	+13.02%	-20.42%	2.07B
Average	+1.93%	+4.28%	+18.17%	+21.46%	40.16B
Weighted average by Cap.	+3.96%	+5.43%	+49.56%	+9.36%

	2017	2018
Net sales	30.17M 198M 26.5M 24.41M 22.83M 42.81M 2.85B 43.6M 293M 113M 1.4B 113M 111M 4.88B	39.49M 259M 34.69M 31.96M 29.89M 56.05M 3.73B 57.08M 383M 149M 1.84B 148M 145M 6.38B
Net income	-9.54M -62.63M -8.38M -7.72M -7.22M -13.54M -900M -13.79M -92.65M -35.89M -444M -35.83M -35.05M -1.54B	-5.28M -34.69M -4.64M -4.28M -4M -7.5M -499M -7.64M -51.32M -19.88M -246M -19.85M -19.41M -854M
Net Debt	18.05M 118M 15.86M 14.61M 13.66M 25.62M 1.7B 26.09M 175M 67.9M 840M 67.79M 66.3M 2.92B	29.38M 193M 25.81M 23.78M 22.24M 41.7M 2.77B 42.47M 285M 111M 1.37B 110M 108M 4.75B